Beyondspring Inc (BYSI)

Sep 3, 2026, 8:00 AM EDT - 19 days ago

BeyondSpring Proxy statement: Proxy filing

Sep 3, 2026, 8:00 AM EDT - 19 days ago

BeyondSpring Proxy statement: Proxy filing

Aug 31, 2026, 7:00 AM EDT - 22 days ago

BeyondSpring Slides: Investor presentation

Aug 14, 2026, 5:15 PM EDT - 5 weeks ago

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

BeyondSpring Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

BeyondSpring Earnings release: Q2 2026

Jul 9, 2026, 7:00 AM EDT - 2 months ago

BeyondSpring Slides: Corporate presentation

2026-06-04T11:13:44.000Z - 3 months ago

BeyondSpring appoints Min Qiu as CEO, Na Li as CFO

Jun 4, 2026, 7:00 AM EDT - 3 months ago

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

2026-06-02T11:45:24.000Z - 3 months ago

BeyondSpring announces updated data from 303 Study

Jun 2, 2026, 7:00 AM EDT - 3 months ago

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

May 18, 2026, 7:00 AM EDT - 4 months ago

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

May 13, 2026, 7:00 AM EDT - 4 months ago

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 4 months ago

BeyondSpring Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

BeyondSpring Quarterly report: Q1 2026

Apr 22, 2026, 7:00 AM EDT - 5 months ago

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

Apr 22, 2026, 7:00 AM EDT - 5 months ago

BeyondSpring Slides: Corporate presentation

Mar 25, 2026, 4:30 PM EDT - 6 months ago

BeyondSpring Files 2025 Annual Report on Form 10-K

Mar 25, 2026, 10:30 AM EDT - 6 months ago

BeyondSpring Annual report: Q4 2025

Mar 25, 2026, 10:30 AM EDT - 6 months ago

BeyondSpring Earnings release: Q4 2025

Feb 9, 2026, 7:15 AM EST - 7 months ago

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

2025-12-12T12:05:36.000Z - 9 months ago

BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress

Dec 12, 2025, 7:00 AM EST - 9 months ago

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

2025-12-11T12:10:15.000Z - 9 months ago

BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC

2025-11-12T12:06:18.000Z - 10 months ago

BeyondSpring reports Q3 EPS (4c) vs (5c) last year

Nov 12, 2025, 7:00 AM EST - 10 months ago

BeyondSpring Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BeyondSpring Earnings release: Q3 2025

2025-08-13T12:11:06.000Z - 1 year ago

BeyondSpring reports Q2 EPS (10c) vs (4c) last year

Aug 13, 2025, 8:00 AM EDT - 1 year ago

BeyondSpring Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

BeyondSpring Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeyondSpring Proxy statement: Proxy Filing

Aug 6, 2025, 8:00 AM EDT - 1 year ago

BeyondSpring Proxy statement: Proxy Filing

2025-07-07T11:20:49.000Z - 1 year ago

BeyondSpring announces publication of human clinical study on plinabulin

Jul 7, 2025, 7:00 AM EDT - 1 year ago

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

2025-06-03T11:05:36.000Z - 1 year ago

BeyondSpring presents interim phase 2 data on 303 study

Jun 3, 2025, 7:00 AM EDT - 1 year ago

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

May 12, 2025, 4:30 PM EDT - 1 year ago

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:00 PM EDT - 1 year ago

BeyondSpring Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

BeyondSpring Earnings release: Q1 2025

Mar 27, 2025, 12:00 PM EDT - 1 year ago

BeyondSpring Slides: Corporate Presentation

2025-03-27T11:17:24.000Z - 1 year ago

BeyondSpring reports FY24 EPS (21c) vs. (34c) last year

2025-03-27T11:17:10.000Z - 1 year ago

BeyondSpring announces expected 2025 milestones

Mar 27, 2025, 7:05 AM EDT - 1 year ago

BeyondSpring Files 2024 Annual Report on Form 10-K

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BeyondSpring Earnings release: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BeyondSpring Annual report: Q4 2024

2025-01-28T12:10:43.000Z - 1 year ago

BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly

LLY

Jan 28, 2025, 7:00 AM EST - 1 year ago

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

Jan 28, 2025, 7:00 AM EST - 1 year ago

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

2024-11-11T13:20:16.000Z - 1 year ago

BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin

Nov 11, 2024, 8:00 AM EST - 1 year ago

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Oct 2, 2024, 4:11 PM EDT - 1 year ago

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume

2024-09-16T11:21:08.000Z - 2 years ago

BeyondSpring presents final data analysis of DUBLIN-3 Phase 3 study

2024-09-16T11:10:24.000Z - 2 years ago

BeyondSpring presented interim Phase 2 data on 303 Study

MRK

Sep 16, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Sep 16, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

2024-09-10T11:15:47.000Z - 2 years ago

BeyondSpring announces Dublin-3 final phase 3 efficacy data

Sep 3, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Aug 12, 2024, 4:00 PM EDT - 2 years ago

BeyondSpring Earnings release: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

Jul 2, 2024, 8:00 AM EDT - 2 years ago

BeyondSpring Registration statement: Registration Filing

2024-06-12T21:14:51.000Z - 2 years ago

BeyondSpring files to sell 10M ordinary shares

Jun 12, 2024, 8:00 AM EDT - 2 years ago

BeyondSpring Registration statement: Registration Filing

2024-05-16T12:17:26.000Z - 2 years ago

BeyondSpring announces R&D day on new Plinabulin strategy

May 16, 2024, 8:00 AM EDT - 2 years ago

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 15, 2024, 10:00 AM EDT - 2 years ago

BeyondSpring Transcript: R&D Day 2024

May 15, 2024, 10:00 AM EDT - 2 years ago

BeyondSpring Slides: FY 2024

May 3, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 2, 2024, 11:00 AM EDT - 2 years ago

BeyondSpring Slides: Corporate Presentation

Apr 30, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Annual report: Q4 2023

Apr 30, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Earnings release: Q4 2023

Apr 29, 2024, 5:30 PM EDT - 2 years ago

BeyondSpring Files 2023 Annual Report on Form 20-F

Apr 29, 2024, 5:30 PM EDT - 2 years ago

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

2024-03-25T11:15:30.000Z - 2 years ago

BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP

Mar 25, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Jan 10, 2024, 3:00 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

Dec 18, 2023, 4:30 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Nov 7, 2023, 8:30 AM EST - 2 years ago

BeyondSpring Transcript: Conference

Nov 7, 2023, 8:30 AM EST - 2 years ago

BeyondSpring Slides: Conference

Nov 7, 2023, 7:00 AM EST - 2 years ago

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

Oct 23, 2023, 7:45 AM EDT - 2 years ago

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

Sep 27, 2023, 10:00 AM EDT - 2 years ago

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

Sep 7, 2023, 8:00 AM EDT - 3 years ago

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

May 18, 2023, 8:30 AM EDT - 3 years ago

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

Apr 18, 2023, 4:30 PM EDT - 3 years ago

BeyondSpring Files 2022 Annual Report on Form 20-F

Apr 18, 2023, 4:30 PM EDT - 3 years ago

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

Apr 18, 2023, 8:00 AM EDT - 3 years ago

BeyondSpring Annual report: Q4 2022

Jan 9, 2023, 4:30 PM EST - 3 years ago

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

Dec 13, 2022, 8:00 AM EST - 3 years ago

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

Sep 13, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Aug 29, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

May 27, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

Apr 14, 2022, 9:04 AM EDT - 4 years ago

BeyondSpring Files 2021 Annual Report on Form 20-F

Apr 14, 2022, 8:00 AM EDT - 4 years ago

BeyondSpring Earnings Call Transcript: Q4 2021

Apr 14, 2022, 8:00 AM EDT - 4 years ago

BeyondSpring Annual report: Q4 2021

Apr 14, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

Apr 8, 2022, 8:00 AM EDT - 4 years ago

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

Jan 11, 2022, 4:05 PM EST - 4 years ago

BeyondSpring Announces Organizational Streamlining

Dec 30, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Dec 15, 2021, 7:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

Dec 10, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Dec 1, 2021, 8:13 AM EST - 4 years ago

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says